SCHEMBL26330152

SCHEMBL26330152

NC1CCC(n2cc(Br)cn2)CC1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMYD3 Q9H7B4 4/20 0.37
KDM5A P29375 1/20 0.36
PIK3CD O00329 1/20 0.35
PIK3CA P42336 1/20 0.35
PIK3CB P42338 1/20 0.35
PI4KA P42356 1/20 0.35
PIK3CG P48736 1/20 0.35
PI4KB Q9UBF8 1/20 0.35
ACHE P22303 3/20 0.34
MPO P05164 1/20 0.33
WDR5 P61964 1/20 0.32
RET P07949 1/20 0.32
MELK Q14680 1/20 0.31
AXL P30530 1/20 0.31
TYRO3 Q06418 1/20 0.31
MERTK Q12866 1/20 0.31
CHRNB2 P17787 2/20 0.30
CHRNA4 P43681 2/20 0.30
RIPK2 O43353 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26330141 1.00 SMYD3 (0.37) SMYD3KDM5APIK3CDPIK3CAPIK3CB
Hydrochloric Acid SCHEMBL25273618 0.98 SMYD3 (0.36) SMYD3KDM5APIK3CDPIK3CAPIK3CB
SCHEMBL1404089 0.90
SCHEMBL574364 0.82 ACHE (0.47) KDM5AACHEMPOWDR5CHRNB2
SCHEMBL2696054 0.82 ACHE (0.44) KDM5AACHEMPOWDR5CHRNB2
SCHEMBL17121177 0.81 ACHE (0.46) KDM5AACHEMPOWDR5CHRNB2
SCHEMBL16758445 0.81 ACHE (0.46) KDM5AACHEMPOWDR5CHRNB2
SCHEMBL2799494 0.80 KDM5A (0.40) KDM5APIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL16899743 0.80 ACHE (0.34) KDM5AACHEMPOWDR5
SCHEMBL16899842 0.80 ACHE (0.34) KDM5AACHEMPOWDR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230233692-A1 COMPOUNDS FOR TARGETED DEGRADATION OF RET C4 THERAPEUTICS, INC. (US) 2023-07-27 US disclosed
US-20230233692-A1 COMPOUNDS FOR TARGETED DEGRADATION OF RET C4 THERAPEUTICS, INC. (US) 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230233692-A1 COMPOUNDS FOR TARGETED DEGRADATION OF RET RET, HRAS, RBX1 SMYD3 2518/4885KDM5A 2668/4885PIK3CD 2317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.